Pembrolizumab plus lenvatinib (P plus L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).

被引：0
|
作者：
Rane, Pratik
Yan, Kevin
Schmidinger, Manuela
Peer, Avivit
Druyts, Eric
Burgents, Joseph E.
Sundaram, Murali
机构：
[1] Merck & Co Inc, North Wales, PA USA
[2] Pharmalyt Grp, Vancouver, BC, Canada
[3] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[4] Rambam Hlth Care Campus, Haifa, Israel
[5] Merck & Co Inc, Rahway, NJ USA
[6] Merck Sharp & Dohme LLC, Rahway, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
281-5277-5597; 298-4770-10048-7646-2344; 6; 2; 3615; 137; 3581; 14; 3585; 3605; 171; 3583; 3; 1; 38092-18643;
D O I：
10.1200/JCO.2024.42.4_suppl.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [31] Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
    Geynisman, Daniel M.
    Kish, Jonathan K.
    Falkenstein, Angelica
    Huo, Stephen
    Del Tejo, Viviana
    Rosenblatt, Lisa
    Guttenplan, Sarah
    Balanean, Alexandrina
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] A COST-EFFCTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS AXITINIB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Gu, J.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [33] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Jun Chen
    Gaoyun Hu
    Zhuo Chen
    Xiaomin Wan
    Chongqing Tan
    Xiaohui Zeng
    Zeneng Cheng
    Clinical Drug Investigation, 2019, 39 : 931 - 938
  • [34] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Chen, Jun
    Hu, Gaoyun
    Chen, Zhuo
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    Cheng, Zeneng
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 931 - 938
  • [35] EXPLORING HIDDEN SURVIVAL HETEROGENEITY AMONG FIRST-LINE (1L) INTERMEDIATE/POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VIA PARAMETRIC MIXTURE MODELS (PMM)
    Hunger, M.
    George, S.
    Dyer, M.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2023, 26 (06) : S287 - S287
  • [36] Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
    Gajra, Ajeet
    Jeune-Smith, Yolaine
    Vaishampayan, Ulka N.
    Rupard, Skyler
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [38] Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).
    Mantia, Charlene
    Jegede, Opeyemi
    Regan, Meredith M.
    Atkins, Michael B.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Prognostic factors for Overall Survival (OS) in patients receiving First-line (1L) Nivolumab plus Ipilimumab (NIVO plus IPI) for advanced/metastatic Renal Cell Carcinoma (aRCC) in a real-world setting in Germany
    Bedke, J.
    Gruenwald, V.
    Mueller-Huesmann, H.
    Belz, H.
    Von Der Heyde, E.
    Boegemann, M.
    Strauss, A.
    Vaz, L.
    Bluhmki, T.
    Herber, M.
    Groetzinger, S.
    Grimm, M-O.
    EUROPEAN UROLOGY, 2024, 85 : S1844 - S1845
  • [40] Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis
    Rizzo, Alessandro
    Mollica, Veronica
    Santoni, Matteo
    Rosellini, Matteo
    Marchetti, Andrea
    Ricci, Angela Dalia
    Grilli, Giada
    Greco, Alba
    Montironi, Rodolfo
    Ardizzoni, Andrea
    Massari, Francesco
    IMMUNOTHERAPY, 2021, 13 (09) : 783 - 793
12345